Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC: A Multi-center Prospective Study in China

NCT07674524 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07674524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC: A Multi-center Prospective Study in China
Lead sponsor
Sun Yat-sen University
Phase
Observational
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 31, 2029
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene mutation, alk-positive, hyperlipidemia, non-small cell lung cancer (nsclc)